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SUMMARY
Exome sequencing is an effective strategy for identifying human disease genes. However, this 
methodology is difficult in late-onset diseases where limited availability of DNA from informative 
family members prohibits comprehensive segregation analysis. To overcome this limitation, we 
performed an exome-wide rare variant burden analysis of 363 index cases with familial ALS 
(FALS). The results revealed an excess of patient variants within TUBA4A, the gene encoding the 
Tubulin, Alpha 4A protein. Analysis of a further 272 FALS cases and 5,510 internal controls 
confirmed the overrepresentation as statistically significant and replicable. Functional analyses 
revealed that TUBA4A mutants destabilize the microtubule network, diminishing its 
repolymerization capability. These results further emphasize the role of cytoskeletal defects in 
ALS and demonstrate the power of gene-based rare variant analyses in situations where causal 
genes cannot be identified through traditional segregation analysis.
INTRODUCTION
The identification of mutations for human disorders is critical for our understanding of their 
pathogenesis. Although numerous studies have successfully used exome sequencing to 
identify novel disease genes, this approach is still limited by the fact that each individual 
harbors many rare variants, thus requiring DNA from multiple affected individuals from an 
affected family to be successful. Unfortunately, for many diseases the collection of multiple 
affected samples from the same family can be difficult. This is especially true for familial 
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amyotrophic lateral sclerosis (FALS), a late-onset, rapidly progressive neurodegenerative 
disease. As such, there is a need to develop approaches to use individual affected cases to 
identify disease genes. Exome-wide rare variant analysis has been proposed as a promising 
alternative strategy (Panoutsopoulou et al., 2013; Stitziel et al., 2011). By this approach, the 
total number of gene variants seen in cases is compared to that in controls. Threshold minor 
allele frequency and possibly functional significance filters are implemented to prevent 
statistical noise from common or neutral variants masking true gene associations. 
Importantly, although an abundance of variants in cases suggests the presence of pathogenic 
mutations, an associated variant set will still likely include neutral variants in both cases and 
controls. Since it does not rely on related samples, we decided to use this approach to 
identify novel causative genes for FALS.
RESULTS
We performed exome sequencing on a discovery cohort of 363 index cases (i.e., one 
affected sample per family) from six countries (Supplemental Experimental Procedures 
available online) devoid of mutations/repeat expansions in known ALS genes (SOD1, 
C9orf72, TARDBP, FUS, PFN1, UBQLN2, OPTN, VCP, and ANG). An average of 3.2 × 109 
target bases was sequenced per sample to an average depth of 90.4×. Control exome data 
included 4,300 European Americans available through the NHLBI’s Exome Variant Server 
(EVS) (Tennessen et al., 2012) and 31 internally sequenced samples. As proof of principle, 
we spiked our sample set with nine FALS exomes with known causative mutations (six in 
SOD1 and three in VCP). The analysis was restricted to the 12,487 genes fulfilling all 
quality control filters and to variants either predicted to be damaging by PolyPhen-2 or 
resulting in a stop gain/loss. Variants were also only considered if they exhibited minor 
allele frequencies less than 0.04%, in keeping with previously reported ALS mutations 
(Chiò et al., 2012; Kenna et al., 2013) (Supplemental Experimental Procedures). The 
significance of disease associations following multiple test correction (Pcorrected) was 
calculated using permutation procedures (Kiezun et al., 2012). Strong signals of disease 
association were observed for SOD1 (6 cases [1.6%] versus 0 controls, p = 5.5 × 10−8, 
Pcorrected = 6.2 × 10−4) and VCP (3 cases [0.8%] versus 0 controls, p = 1.1 × 10−4, Pcorrected 
= 0.73) (Figure 1A and Figure S1). Excluding SOD1, the top hit from our analysis was 
TUBA4A, encoding the Tubulin, Alpha 4A protein (4 cases [1.1%] versus 0 controls, p = 9.1 
× 10−6, Pcorrected = 0.09). Similar significance for TUBA4A was also obtained when using 
alternative bioinformatic tools to identify putatively damaging variants (SIFT, GERP, 
MutationTaster, and phyloP). TUBA4A ranked first or second in all tests (Table S1 and 
Figure S1), while no other gene ranked in the top ten hits for all five tests. Besides TUBA4A, 
our strategy revealed other strong candidate genes for FALS (Figure 1A; Table S1), 
including MATR3, responsible for distal myopathy 2 and recently identified as causative for 
FALS (Johnson et al., 2014). Based on these results, we further investigated TUBA4A as a 
candidate gene associated with FALS.
Exome sequencing revealed a total of five nonsynonymous TUBA4A changes, all localized 
in exon 4 and confirmed by Sanger sequencing (Table S2). None of them were observed in 
the 4,300 EVS controls and all occurred at highly conserved positions (Figure 1B). The 
mutations included two missense changes in the same residue (R320C/H) and a nonsense 
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mutation (W407X) removing the last 41 amino acids. This C-terminal region contacts the β-
tubulin subunit as well as the motor domain of kinesins and other microtubule-associated 
proteins (Howes et al., 2014; Liu et al., 2012) (Figure 1C). Additional missense changes 
included R215C and A383T mutations. PolyPhen-2 predicted four of the five mutations to 
be deleterious (Table S2). In contrast, only three nonsynonymous changes were observed in 
the 4,300 EVS controls (V68A, I276V, and V375M), all predicted to be benign. No relatives 
of the affected patients were available to test segregation.
To further evaluate TUBA4A as a causative ALS gene, we sequenced an independent 
replication cohort comprising a further 272 index FALS cases and 5,510 internal European 
American controls for rare damaging exon 4 variants. Reimplementation of the variant 
filtering strategies employed during the discovery analysis and subsequent testing using 
Fisher’s exact method revealed a significant excess of mutation carriers among patients (2 
cases [0.65%] versus 2 controls [0.04%], p = 1.5 × 10−2). A combined analysis of the 
discovery and replication cohorts resulted in a statistically significant overabundance of rare 
variants after multiple test correction (OR = 36 [95% CI: 10–210], p = 4.3 × 10−7, Pcorrected 
= 4.2 × 10−3). Of the two mutations observed in the replication cohort, a T145P variant 
segregated with disease within the family, while a K430N variant was not detected in an 
affected first cousin of the sequenced proband (Figure S1C), suggesting that this is either a 
neutral polymorphism, as is often observed in rare variant analyses, or the two affected 
family members are phenocopies. Variants identified in controls included E386K and 
G365E substitutions but none of the variants detected in FALS patients from either the 
discovery or replication cohorts. Sequencing of the entire coding region in 1,355 sporadic 
ALS (SALS) cases also identified a G43V mutation in a single sample (Table S2). This 
variant was predicted to be benign by PolyPhen-2 and detected within 1 control from the 
internal replication panel. No TUBA4A mutations were identified in 131 ALS samples (89 
FALS and 42 SALS) with known mutations/repeat expansions.
All patients carrying TUBA4A mutations had spinal-onset, classical ALS, with upper and 
lower motor neuron signs. Two cases also developed a cognitive decline of frontal type, 
consistent with a diagnosis of frontotemporal dementia (FTD) and another had a first-degree 
relative with FTD (Figure S1 and Table S3). Screening of 1,053 samples analyzed by the 
1000 Genome project and 2,200 African Americans from the EVS revealed the A383T 
mutation within a single individual of African ancestry. Therefore, with the exception of 
A383T and G43V, the set of observed patient variants were not detected within a total of 
13,023 control samples (Table S4).
TUBA4A Mutants Display Altered Incorporation into Microtubules
Since several causative ALS proteins form insoluble inclusions in postmortem brain tissues 
and in cell culture, we investigated the ability of TUBA4A mutants to aggregate by 
expressing hemagglutinin (HA)-tagged TUBA4A constructs in primary motor neurons 
(PMNs) and HEK293 cells. Interestingly, the W407X mutant did not incorporate into the 
microtubule network and formed small ubiquitinated cytoplasmic inclusions in ~40% of 
transfected PMNs and ~85% of transfected HEK293 cells (Figures 2A and 2B; Figure S2). 
Immunohistochemistry of brain and spinal cord tissue from SALS cases (without mutations) 
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yielded a clear staining of the perikarya and neuropil region in both the spinal cord and 
motor cortex; however, no TUBA4A aggregates were identified (Figure S2). No 
coaggregation was observed in cells coexpressing an aggregation-prone TDP-43 C-terminal 
fragment and wild-type TUBA4A (Figure S2). While the other TUBA4A mutants formed 
cytoplasmic inclusions in 10%–30% of transfected HEK293 cells (data not shown), no 
aggregation was observed in PMNs. However, subtle alterations in their cytoplasmic 
distribution were observed, such as a more diffuse staining compared to the wild-type 
protein, which was mainly incorporated into the microtubule network (Figure 2A). We thus 
investigated the ability of mutant TUBA4A to efficiently form microtubules using a cell-free 
system to quantify its incorporation into α-/β-tubulin dimers (Cleveland et al., 1978; Jaglin 
et al., 2009; Tian et al., 2010). Each mutant was subjected to in vitro translation in rabbit 
reticulocyte lysate that contains all components needed to form tubulin dimers. The products 
were then analyzed by nondenaturing gel electrophoresis to measure incorporation of the 
translated recombinant protein into tubulin dimers. Interestingly, TUBA4AW407X yielded no 
discernible dimers, while the A383T and both R320 mutants displayed significantly lower 
levels of assembly relative to the wild-type protein (Figures 2C and 2D). The other mutants 
did not differ from the control, save for a small but reproducible migration difference for 
TUBA4AR215C. In parallel, we tested the incorporation of mutant TUBA4A into 
microtubules in cultured cells. We chose primary astroglial cells, as they have a large 
cytoplasm and a relatively long cell cycle that result in an extensive and stable microtubule 
network. We performed an unbiased analysis of the cytoskeletal incorporation of HA-tagged 
TUBA4A constructs. The ratio between the fluorescence intensities of the filamentous 
versus overall staining, ranging from 1 to 0, was used to categorize each cell as normal (1–
0.75), mild (0.75–0.5), moderate (0.5–0.25), or severe (0.25–0) (Figures 2E and 2F and 
Figure S3). The wild-type HA-tagged TUBA4A protein yielded nearly 70% of cells 
displaying a high level of microtubule incorporation. In contrast, several mutants displayed 
an altered incorporation into microtubules. In particular, the W407X yielded the most 
dramatic effect with an absence of tagged protein in the microtubule network and the 
presence of multiple aggregate-like inclusions. The R320C/H, A383T, and R215C mutants 
all displayed a significantly different distribution relative to the wild-type, but no differences 
were detected for the G43V protein.
TUBA4A Mutants Disrupt Microtubule Dynamics and Stability through a Dominant-
Negative Mechanism
We next determined whether TUBA4A mutants affected microtubule dynamics by testing 
the ability of transfected COS7 cells to recover after transient microtubule depolymerization 
(Figure 3) (Gilissen et al., 2011; Tian et al., 2008, 2010). For this assay, the wild-type, 
R320C, and W407X proteins were compared, as these mutants displayed an intermediate 
and severe phenotype, respectively, in the previous experiments. While ~80% of cells 
transfected with TUBA4AWT formed centrosomes positive for the HA-tagged TUBA4A 
protein within 5 min of nocodazole removal, only ~20% of TUBA4AR320C-transfected cells 
formed new microtubules containing the mutant protein at 15 min. The expression of mutant 
TUBA4A also impaired the ability of the endogenous protein to form microtubules, as only 
50% of the cells contained TUBA4A-positive microtubules after 15 min, compared to ~90% 
in wild-type-transfected cells (Figures 3A and 3B). Similar results were also observed in 
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cells containing TUBA4AW407X-positive aggregates. On the contrary, cells expressing the 
TUBA4AW407X mutant without the presence of aggregates did not display any defect in the 
rate of microtubule repolymerization (Figures 3C and 3D). These results suggest that mutant 
TUBA4A by incorporating into the microtubules may disrupt their dynamics through a 
dominant-negative mechanism.
To pursue this hypothesis, we investigated whether TUBA4A mutants would influence the 
overall stability of the microtubule network. PMNs expressing wild-type and mutant 
TUBA4A constructs were permeabilized with 0.1% Triton X-100 to extract soluble proteins 
before fixation and immunostained for HA-TUBA4A and β-tubulin. Under these conditions, 
the cytoskeleton was largely preserved in wild-type-transfected neurons, whereas each of the 
missense mutants resulted in decreased HA-TUBA4A and β-tubulin immunofluorescence 
(Figures 4A–4C). Furthermore, the levels of α-tubulin acetylation, which have been shown 
to correlate with increased microtubule stability (Matsuyama et al., 2002; Piperno et al., 
1987), were significantly reduced in mutant TUBA4A-expressing PMNs (Figures 4D and 
4E). Of note, the G43V mutation, which is uniquely localized to the protein N terminus, did 
not impair tubulin acetylation, suggesting that defective binding of the acetyl-transferase 
αTAT1 to α-tubulin C-terminal tail (Howes et al., 2014; Panoutsopoulou et al., 2013; 
Stitziel et al., 2011), where TUBA4A mutations are clustered, may be responsible for this 
effect. Together, these results further suggest that missense mutants of TUBA4A weaken the 
microtubule network by a dominant-negative mechanism.
DISCUSSION
To summarize, we have used an unbiased case-control exome-sequencing study to identify a 
statistically significant and replicable excess of rare damaging TUBA4A variants in FALS. 
Disease-associated variants affect conserved residues and in most cases are absent in over 
13,000 controls. The positive identification of samples with mutations in the SOD1 and VCP 
genes, as well as in the newly discovered ALS gene MATR3 within the initial cohort, further 
proves the validity of our approach. Though our burden approach demonstrated the 
importance of a specific class of TUBA4A variants, a limitation is that it is not informative as 
to the effects of individual variants. Thus, not all reported patient mutations may be 
pathogenically relevant or act with equal penetrance. An example of this is the K430N 
alteration not segregating in an affected first cousin. However, our results from biological 
characterization provided strong evidence to support a deleterious effect of most variants. 
Specifically, FALS-associated variants (1) inefficiently form α-/β- tubulin dimers in vitro,
(2) display decreased incorporation into microtubules in cultured cells, and (3) inhibit 
microtubule network assembly and reduce structural stability. Based on these data, 
TUBA4A mutants appear to disrupt microtubule dynamics and stability through a dominant-
negative mechanism. Interestingly, the truncation mutant TUBA4AW407X is deficient in 
forming dimers or incorporating into the microtubule network, suggesting that it may have a 
decreased ability to act as a dominant negative. This is illustrated by our observation that in 
cells expressing the W407X mutant without aggregates, there is no obvious defect in the rate 
of microtubule repolymerization. However, since TUBA4AW407X shows aggregation 
propensities analogous to other ALS-associated mutant proteins, its deleterious effect may 
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be through a different mechanism, such as trapping tubulin-binding proteins into aggregates 
or by overburdening the ubiquitin proteasome system.
Mutations in at least seven other tubulin family members (TUBA1A [Keays et al., 2007; 
Kumar et al., 2010; Poirier et al., 2007], TUBA8 [Abdollahi et al., 2009], TUBB2B [Jaglin et 
al., 2009], TUBB3 [Poirier et al., 2010; Tischfield et al., 2010], TUBB5 [Breuss et al., 2012], 
TUBB4A [Hersheson et al., 2013; Tian et al., 2008], and TUBG1 [Poirier et al., 2013]) have 
been described to cause several neurodevelopmental and neurodegenerative disorders. 
Moreover, the progressive motor neuronopathy (pmn) mutant mouse, a commonly used 
model for human motor neuron disease, bears a mutation in the Tubulin-specific Chaperone 
E (TBCE) gene (Bömmel et al., 2002; Martin et al., 2002). Most mutant tubulin proteins 
show similar functional defects compared to TUBA4A mutants, such as impaired 
dimerization and microtubule incorporation and yet cause very different phenotypes. 
Interestingly, results from the BrainSpan Atlas and in developing mouse brain tissue show 
that most α- and β-tubulin subunits responsible for developmental defects are highly 
expressed during brain development and decrease with age, whereas TUBA4A levels 
increase dramatically (>50-fold) with age (Figure S4). Furthermore, similar to TUBA4A, 
expression of TUBB4A also increases over time and mutations in this gene are responsible 
for a disease with an onset age of 15–37 years (torsion dystonia type 4) (Hersheson et al., 
2013). These observations may partially explain the difference between the 
neurodevelopmental and late-onset symptoms associated to the different tubulin mutations.
TUBA4A is ubiquitously expressed in human tissues with its highest expression in brain 
(Rustici et al., 2013). Although a downregulation of α-tubulin subunit genes has been 
reported in motor neurons of SALS patients (Jiang et al., 2005), no specific role has been 
described for TUBA4A in motor neurons so far. TUBA4A joins other ALS-associated genes 
encoding for cytoskeletal proteins, such as PFN1 (Wu et al., 2012), DCTN1 (Puls et al., 
2003), PRPH (Gros-Louis et al., 2004), and NEFH (Al-Chalabi et al., 1999), thus 
strengthening the hypothesis that alterations affecting the cytoskeleton architecture and 
dynamics have a major role in ALS pathogenesis.
EXPERIMENTAL PROCEDURES
Exome Sequencing and Rare Variant Analysis
Ethical approval for this study was received by the IRBs of the participating institutions. 
Exome sequencing reads were aligned to a human reference (hg19) using Burrows-Wheeler 
Aligner and processed using the Genome Analysis ToolKit. Rare variant analyses were 
performed by logistic regression of case-control status with respect to the aggregated count 
of minor alleles in a given gene window. For each p value from the observed data set 
analysis, Pcorrected was calculated as the proportion of permuted data sets where an 
association of equal or greater significance was observed across any gene.
Motor Neuron Culture and Transfection
PMNs were cultured from embryonic day 12.5 embryos and transfected at 2 days in vitro, as 
previously described (Fallini et al., 2010).
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Quantification of Microtubule Incorporation
Using ImageJ, a region of interest (ROI) was selected for each HA-TUBA4A-positive cell 
and the signal was thresholded to remove background noise. A circularity filter (circularity 
index ≥ 0.2) was then applied to remove granular staining. The ratio between the 
fluorescence intensities of the filtered cytoskeleton versus the thresholded ROI yielded an 
incorporation index ranging from 0 (no incorporation) to 1 (complete microtubule 
incorporation).
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Figure 1. Rare Variant Analysis Identifies TUBA4A Mutations in FALS
(A) Manhattan plot displaying permutation-based corrected p values generated by a rare 
variant analysis of FALS. The dotted line represents a Pcorrected = 0.05. The points in 
yellow, red, and black for TUBA4A denote the p value for the discovery, replication, and 
joint analyses, respectively. (B) The evolutionary conservation of TUBA4A mutations is 
displayed. Mutated residues are shown in red. (C) The interactions of bovine TUBA1B and 
TUBB2B with the rat kinesin KIF5B (Protein Data Bank accession number 4ATX) are 
shown using the PyMOL Molecular Graphics System (v.1.5.0.5). All relevant residues are 
identical between bovine TUBA1B and human TUBA4A. Light blue, α-tubulin; green, β-
tubulin; orange, kinesin; red, mutant or deleted residues identified in this study; spheres, 
residues involved in interprotein interactions. As shown, the C-terminal region interacts with 
both β-tubulin and the kinesin motor domain.
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Figure 2. Mutant TUBA4A Alters Microtubule Polymerization
(A) PMNs transfected with HA-tagged TUBA4A constructs. (B) HEK293 cells expressing 
wild-type or mutant HA-TUBA4A were immunostained for ubiquitin. Ubiquitin-positive 
aggregates were visible only in the HA-TUBA4AW407X-transfected cells. (C) 
Nondenaturing (top) and SDS-gel electrophoresis (bottom) of HA-TUBA4A constructs after 
in vitro translation. (D) The intensity of the bands representing the α-/β-tubulin dimers was 
quantified. Bars represent mean and SEM (one-way ANOVA and Dunnett’s post hoc test, n 
= 6, *p < 0.05, ***p < 0.001). (E) Representative images of primary astroglial cells 
transfected with the HA-TUBA4A constructs. (F) The ratio between HA-TUBA4A protein 
distributions in filaments versus its overall levels was measured and distributed into four 
categories from mainly filamentous to mainly diffuse. The frequency of each phenotype was 
compared between the wild-type and mutant proteins (Kolmogorov-Smirnov test; n = 75–90 
cells per condition from 3 experiments, **p < 0.01, ***p < 0.001). From left to right, bars 
represent the relative frequencies of the normal, mild, moderate, and severe phenotypes. 
Red, HA; green, ubiquitin; blue, DAPI. White boxes indicate the regions enlarged in the 
insets. Scale bars, 10 μm.
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Figure 3. Mutant TUBA4A Alters Microtubule Dynamics
(A and C) Representative images of nocodazole-treated COS7 cells expressing wild-type 
and mutant TUBA4A (A, TUBA4AR320C; C, TUBA4AW407X). Cells were allowed to 
recover in nocodazole-free medium for 2.5, 5, 10, or 15 min prior to fixation. Red, HA; 
green, TUBA4A; blue, DAPI. White boxes indicate the regions enlarged in the insets. Scale 
bars, 10 μm. (B and D) The percentage of cells containing microtubules positive for the HA-
tagged or the endogenous TUBA4A protein was quantified from more than 100 cells per 
condition from 3 independent experiments and compared between wild-type and mutant 
TUBA4A (B, TUBA4AR320C; D, TUBA4AW407X). Points represent mean and SEM (one-
way ANOVA and Dunnett’s post hoc test; *p < 0.05, **p < 0.01, ***p < 0.001).
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Figure 4. Mutant TUBA4A Destabilizes the Microtubule Network
(A) PMNs transfected with wild-type or mutant TUBA4A constructs were permeabilzed 
with 0.1% Triton X-100 for 5 min prior to fixation. (B and C) The fluorescence intensity of 
(B) HA-TUBA4A and (C) β-tubulin was quantified and compared. Bars represent mean and 
SEM (Kruskal-Wallis test, n = 23–34 cells per condition from 3 independent experiments, 
*p < 0.05, **p < 0.01, ***p < 0.001). (D and E) Acetylated tubulin (green) levels were 
measured in PMNs expressing TUBA4A mutants (red). Representative images are shown 
(D). Bars represent mean and SEM (E, one-way ANOVA and Dunnett’s post hoc test, n = 
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30–45 cells per condition from 3 independent experiments, *p < 0.05, **p < 0.01). Scale 
bars, 10 μm.
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